Martin Shkreli's viral peptide thread ignites debate over unapproved research chemicals
Mar 18, 2026
Key Points
- Martin Shkreli posts viral critique of San Francisco's peptide trend, arguing most promoters lack expertise to safely use unapproved research chemicals and lack FDA verification that compounds match labels.
- Shkreli concedes some unapproved drugs have merit but says that expertise is precisely why ordinary people should consult doctors, not self-medicate with understudied compounds.
- A scheduled debate between Shkreli and Max Marchioni from Superpower reveals commercial stakes in the dispute over whether peptide products deserve the hype driving their adoption.
Summary
Martin Shkreli posted a viral thread criticizing the peptide trend sweeping San Francisco. His argument rests on five technical points. Peptides are a narrow class of pharmaceuticals with extremely short half-lives (seconds to minutes), making them inherently weak candidates for effective drugs. Any legitimate drug requires a clearly specified biological target and mechanism of action. Pharmacokinetics—how a substance travels through the body—must be rigorously characterized before human use. Target engagement must be validated through assays. Without double-blind, placebo-controlled clinical trials, claims of efficacy are essentially meaningless.
Most San Francisco health optimizers are not discussing FDA-approved peptide drugs like octreotide, but rather unapproved "research chemicals." Shkreli notes this category is wildly illegal. The regulatory oversight exists because the FDA ensures that what's on a drug label actually matches what's in the bottle. Without that verification, companies could ship inert substances or dangerous molecules and users would have no way to know. He compares self-medicating with untested compounds to performing surgery on yourself or flying a plane without training. It is not that enthusiasts lack intelligence, but that medicine requires specialized knowledge built over years.
When pressed on whether some unapproved drugs might actually be useful, Shkreli concedes the point. He made a living finding such compounds, but that expertise is precisely why ordinary people should not attempt the same. He directly tells the health-optimization crowd to ask a doctor, noting that no healthcare professionals he knows endorse taking unapproved research chemicals.
One commenter pushed back that Shkreli was dismissing the drugs people actually use: retrutide (an Eli Lilly biopharmaceutical in stage three trials) and BPC-157 (which has anecdotal and some clinical support). Shkreli responded that BPC-157 has no meaningful evidence and carries an understudied cancer-growth risk. An implicit tension exists in San Francisco health circles. Some practitioners may be discounting long-term health risks because they believe AGI timelines will solve those problems within a decade anyway. That amounts to betting they will be healthy enough to benefit from future cures before current compound risks materialize.
A debate between Shkreli and Max Marchioni from Superpower (a company that appears to sell peptide products) is scheduled for Monday at noon Pacific. The disagreement carries commercial stakes.